九典制药(300705) - 九典制药调研活动信息

Group 1: Product Development and Market Position - The company believes that Ketoprofen gel patch and Loxoprofen sodium gel patch complement each other in the market, addressing unmet patient needs in the external anti-inflammatory analgesic drug market [1] - Ketoprofen gel patch has started sales, with bidding and listing completed in April 2023, and shipments have begun in certain provinces [2] - Loxoprofen sodium gel patch is primarily sold in hospitals, while the company is expanding sales channels to increase coverage in large and medium-sized chain pharmacies [2] Group 2: Clinical Research and Product Pipeline - Multiple external preparation products are currently undergoing clinical trials, including Lidocaine gel patch, Indomethacin gel patch, and others, with some already approved for clinical use [2] - The barriers to entry in the gel patch field include technical barriers related to drug release systems and lengthy administrative approval cycles [2] Group 3: Financial Performance and Goals - The company expects a year-on-year revenue and net profit growth of 25-35% for 2023, with net profit referring to the profit attributable to shareholders after deducting non-recurring gains and losses [2] - The total amount raised from the convertible bond issuance is expected to be no more than 360 million yuan, which will be used entirely for the development of a high-end formulation R&D industrial park for oral solid preparations [3]